J&J gambles $12.5M in rare Big Pharma bet on a stem cell therapy – FierceBiotech
|
J&J gambles $12.5M in rare Big Pharma bet on a stem cell therapy
FierceBiotech Later this week a little biotech named Capricor is set to begin a Phase II study of its new stem cell therapy with about $20 million in support from the California Institute for Regenerative Medicine. And this morning Johnson & Johnson is stepping up … |
